Modeling anti-tumor function of human T cells

Mouse models have been essential for establishing the role of the T cells in anti-tumor responses, but they have limited utility in translational studies for the testing of candidate therapeutics due to lack of cross-reactivity of many human antibodies to mouse receptors. Most of the human cell-based models for studying anti-tumor T cell responses, however, have significant biological or practical limitations that constrain their usefulness.

In this webinar, Dr. Michael Overstreet from AstraZeneca will discuss the development of a model system to study antigen-specific T cell-mediated cytotoxicity of HLA-matched human tumor cells based on memory anti-viral T cells. This presentation will show how optimizing this model using real-time instrumentation has led to new understanding of the interplay among the dynamic variables that impact the interactions between tumor cells and T cells.

Tune in to learn more about: 

  • Approaches to modeling and studying HLA-restricted anti-tumor T cell responses without access to primary tumor samples
  • Variables that can dramatically impact these types of studies
  • How using both impedance measurement and imaging has impacted our understanding of the dynamics of these assays

Date:
Tuesday, May 5, 2020

Time:
08:00 PDT (Los Angeles)
11:00 EDT (New York)
16:00 BST (London)

Presented by:

Michael G. Overstreet, PhD
Scientist, Oncology Discovery
AstraZeneca, Oncology R&D 

  Register now  

For Research Use Only. Not for use in diagnostic procedures.

©2020 Agilent Technologies